Russia’s Enteromix, a personalized mRNA-based cancer vaccine, has demonstrated 100% efficacy and safety in clinical trials, offering a potential breakthrough in cancer treatment. Developed using technology similar to COVID-19 vaccines, it trains the immune system to eliminate cancer cells without serious side effects. The vaccine awaits final approval from the Ministry of Health for public availability. Read below to know more!
Enteromix, Russia’s cancer vaccine achieves 100% efficacy in clinical trials
